Table 2.

Associations between clinical outcomes and ctDNA mutation status at different timepoints for the overall population

		Recurrence at 6 months		Recurrence at 24 months		Overall progression probability		Death probability		DFS		OS
		n (%)	P	n (%)	P	n (%)	P	n (%)	P	Median (months)	P	Median (months)	P
T1 (n = 76)	MT (n = 28)	2 (7.1)	0.623	7 (25)	0.258	11 (39.3)	0.028	6 (21.4)	0.046	41	0.214	NR	0.077
	WT (n = 48)	2 (4.2)		7 (14.6)		8 (16.7)		2 (4.2)		NR		NR
T2 (n = 76)	MT (n = 20)	4 (20)	0.004	7 (35)	0.042	11 (55)	<0.001	6 (30)	0.003	29	0.001	NR	0.003
	WT (n = 56)	0 (0)		7 (12.5)		8 (14.3)		2 (3.6)		NR		NR
T3 (n = 76)	MT (n = 24)	3 (12.5)	0.09	7 (29.2)	0.120	10 (41.7)	0.023	3 (12.5)	0.702	41	0.129	NR	0.943
	WT (n = 52)	1 (1.9)		7 (13.5)		9 (17.3)		5 (9.6)		NR		NR
T4 (n = 69)	MT (n = 25)	2 (8)	0.617	4 (16)	0.756	7 (28.0)	0.785	3 (12)	1	41	0.600	NR	0.570
	WT (n = 44)	2 (4.5)		9 (20.5)		11 (25)		5 (11.4)		NR		NR
T5 (n = 56)	MT (n = 17)	3 (17.6)	0.079	5 (29.4)	0.739	7 (41.2)	0.339	4 (23.5)	0.228	41	0.746	NR	0.437
	WT (n = 39)	1 (2.6)		9 (23.1)		11 (28.2)		4 (10.3)		NR		NR
T6 (n = 42)	MT (n = 19)	1 (5.3)	0.452	2 (10.5)	0.428	4 (21.1)	1	3 (15.8)	0.644	NR	0.307	NR	0.790
	WT (n = 23)	0 (0)		5 (21.7)		6 (26.1)		2 (8.7)		NR		NR
T7 (n = 31)	MT (n = 12)	2 (16.7)	0.548	3 (25)	0.704	5 (41.7)	0.712	3 (25)	0.364	41	0.935	NR	0.612
	WT (n = 19)	1 (5.6)		6 (33.3)		6 (33.3)		2 (11.1)		NR		NR
T8 (n = 37)	MT (n = 9)	1 (11.1)	0.432	2 (22.2)	1	2 (22.2)	1	1 (11.1)	1	NR	0.680	NR	0.469
	WT (n = 28)	1 (3.6)		5 (17.9)		8 (28.6)		4 (14.3)		34		NR

Highlighted comparisons indicate statistical significance (P < 0.05); NR indicates that median survival was not reached.

ctDNA, circulating tumor DNA; DFS, disease-free survival; MT, mutant; OS, overall survival; WT, wild type.